CanSino Financial Statements From 2010 to 2024
| CJH Stock | EUR 3.66 0.02 0.54% |
Check CanSino Biologics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among CanSino Biologics' main balance sheet or income statement drivers, such as , as well as many indicators such as . CanSino financial statements analysis is a perfect complement when working with CanSino Biologics Valuation or Volatility modules.
CanSino |
CanSino Biologics Company Shares Outstanding Analysis
CanSino Biologics' Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.
Current CanSino Biologics Shares Outstanding | 114.78 M |
Most of CanSino Biologics' fundamental indicators, such as Shares Outstanding, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, CanSino Biologics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Outstanding shares that are stated on company Balance Sheet are used when calculating many important valuation and performance indicators including Return on Equity, Market Cap, EPS and many others.
| Competition |
Based on the latest financial disclosure, CanSino Biologics has 114.78 M of shares currently outstending. This is 36.42% lower than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—Specialty & Generic industry. The shares outstanding for all Germany stocks is 79.93% higher than that of the company.
CanSino Biologics Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining CanSino Biologics's current stock value. Our valuation model uses many indicators to compare CanSino Biologics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across CanSino Biologics competition to find correlations between indicators driving CanSino Biologics's intrinsic value. More Info.CanSino Biologics is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the CanSino Biologics' earnings, one of the primary drivers of an investment's value.About CanSino Biologics Financial Statements
CanSino Biologics stakeholders use historical fundamental indicators, such as CanSino Biologics' revenue or net income, to determine how well the company is positioned to perform in the future. Although CanSino Biologics investors may analyze each financial statement separately, they are all interrelated. For example, changes in CanSino Biologics' assets and liabilities are reflected in the revenues and expenses on CanSino Biologics' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in CanSino Biologics. Please read more on our technical analysis and fundamental analysis pages.
CanSino Biologics Inc. develops, manufactures, and commercializes vaccines in the Peoples Republic of China. CanSino Biologics Inc. was founded in 2009 and is headquartered in Tianjin, the Peoples Republic of China. CANSINO BIOLOGICS operates under Drug ManufacturersSpecialty Generic classification in Germany and is traded on Frankfurt Stock Exchange. It employs 726 people.
Currently Active Assets on Macroaxis
Other Information on Investing in CanSino Stock
CanSino Biologics financial ratios help investors to determine whether CanSino Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in CanSino with respect to the benefits of owning CanSino Biologics security.